Rani Therapeutics Holdings, Inc. (RANI)
NASDAQ: RANI · Real-Time Price · USD
0.5520
+0.0350 (6.77%)
At close: Jun 27, 2025, 4:00 PM
0.5568
+0.0048 (0.87%)
After-hours: Jun 27, 2025, 7:59 PM EDT
RANI Revenue
Rani Therapeutics Holdings had revenue of $172.00K in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $1.20M. In the year 2024, Rani Therapeutics Holdings had annual revenue of $1.03M.
Revenue (ttm)
$1.20M
Revenue Growth
n/a
P/S Ratio
12.84
Revenue / Employee
$11,321
Employees
106
Market Cap
31.76M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
RANI News
- 5 weeks ago - Rani Therapeutics Announces Research Agreement with Chugai - GlobeNewsWire
- 6 weeks ago - Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update - GlobeNewsWire
- 3 months ago - Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update - GlobeNewsWire
- 3 months ago - Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102 - GlobeNewsWire
- 3 months ago - Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 9 months ago - Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants - GlobeNewsWire
- 9 months ago - Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire